Yayın:
Efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors

Basit Görünüm
dc.contributor.authorÇubukcu, Sinem
dc.contributor.authorKanat, Özkan
dc.contributor.authorÇubukcu, Erdem
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorCanhoroz, Mustafa
dc.contributor.authorAvcı, Nilüfer
dc.contributor.authorHartavi, Mustafa
dc.contributor.authorDeligönül, Adem
dc.contributor.authorSeyhan, Serdar
dc.contributor.authorAyyıldız, Aylin
dc.contributor.authorTaşdemir, Ünal
dc.contributor.authorManavoğlu, Osman
dc.contributor.buuauthorÇUBUKÇU, SİNEM
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorCanhoroz, Mustafa
dc.contributor.buuauthorAvcı, Nilüfer
dc.contributor.buuauthorHartavi, Mustafa
dc.contributor.buuauthorDELİGÖNÜL, ADEM
dc.contributor.buuauthorSeyhan, Serdar
dc.contributor.buuauthorAyyıldız, Aylin
dc.contributor.buuauthorTaşdemir, Ünal
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Onkoloji Bilim Dalı
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridJJB-0254-2023
dc.contributor.researcheridJRU-4028-2023
dc.contributor.researcheridJGT-4101-2023
dc.contributor.researcheridDJG-4827-2022
dc.contributor.researcheridCJW-6018-2022
dc.contributor.researcheridCCT-7946-2022
dc.contributor.researcheridCUI-5353-2022
dc.contributor.researcheridJHC-1731-2023
dc.contributor.researcheridDSI-5869-2022
dc.contributor.researcheridKGG-2754-2024
dc.contributor.researcheridKBV-2934-2024
dc.contributor.researcheridFLP-9613-2022
dc.date.accessioned2024-10-08T10:21:41Z
dc.date.available2024-10-08T10:21:41Z
dc.date.issued2014-07-01
dc.description.abstractAim: In this study, the efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) was investigated. Material and Method: A total of 11 imatinib-resistant GIST patients who have sufficient information about their medical treatment and outcome were retrospectively analyzed. Results: Partial response was observed in only two patients, and five patients achieved stable disease. Progression free survival and overall time was 8.8 months and 12 months, respectively. Sunitinib was relatively well tolerated. Almost all patients experienced one or more treatment-related adverse event. Discussion: Based on our limited experience, we concluded that sunitinib is reasonable treatment option for patients with imatinibresistant GIST.
dc.identifier.doi10.4328/JCAM.1375
dc.identifier.issn1309-0720
dc.identifier.issue4
dc.identifier.urihttps://doi.org/10.4328/JCAM.1375
dc.identifier.urihttps://ia801609.us.archive.org/5/items/efficacy-of-sunitinib-in-patients-with-imatinib-resistant-gastrointestinal-stromal-tumors/1375.pdf
dc.identifier.urihttps://hdl.handle.net/11452/46054
dc.identifier.volume5
dc.identifier.wos000215563900013
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherDerman Medical Publ
dc.relation.journalJournal of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCancer
dc.subjectSunitinib
dc.subjectGastrointestinal stromal tumors
dc.subjectGeneral & internal medicine
dc.titleEfficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication375ef438-7ff8-4a42-97a4-74096fac117f
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublicationedfc19d5-ce9e-4fbd-8a24-07492003c264
relation.isAuthorOfPublication.latestForDiscovery375ef438-7ff8-4a42-97a4-74096fac117f

Dosyalar

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications